* OpGen Inc OPGN.OQ OPGN.O is expected to show a fall in
quarterly revenue when it reports results on August 10.
* The Rockville Maryland-based company is expected to
report a
6.9% decrease in revenue to $900 thousand from $967.21 thousand
a year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for OpGen Inc is for a
loss
of 71 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for OpGen Inc
is $3,
above its last closing price of $0.53.
This summary was machine generated August 9 at 02:04 GMT. All
figures in US dollars unless otherwise stated